Weiss Law is investigating Ra Medical Systems, Inc.

NEW YORK, September 13, 2022 /PRNewswire/ — Weiss’ law investigation of possible breaches of fiduciary duty and other violations of law by the board of directors of Ra Medical Systems, Inc. (“Ra ​​Medical” or the “Company”) (NYSE: RMED) as part of the Company’s proposed merger with Catheter Precision, Inc. (“Catheter Precision”). The merger is structured as a reverse stock merger whereby all of Catheter Precision’s convertible promissory notes and outstanding equity interests are to be exchanged for common stock of Ra Medical and options of Catheter Precision assumed by the Company. Upon completion of the transaction, Catheter Precision shareholders are expected to own approximately 80% of the combined company, and Ra Medical shareholders are expected to own only approximately 20% of the combined company.

If you own Medical Ra actions and wish to discuss this survey or have questions about this notice or your rights or interests, visit our website:

Or please contact:

Joshua Rubin, Esq.
Weiss’ law
305 Broadway, 7e Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]

Weiss Law is investigating whether (i) the board of directors of Ra Medical acted in the best interests of the company’s shareholders in agreeing to the proposed transaction, (ii) the merger consideration adequately compensates the shareholders of Ra Medical and (iii) all information regarding the sale process and the evaluation of the transaction will be fully and truthfully disclosed.

Weiss Law has litigated hundreds of shareholder class and derivative actions for breach of corporate and fiduciary duties. We’ve recovered more than $1 billion for defrauded customers and won significant corporate governance relief in many of those cases. If you have information or want legal advice regarding possible corporate wrongdoing (including insider trading, waste of company assets, accounting fraud or misleading information), fraud consumer rights (including false advertising, defective products or other deceptive marketing practices), or anti-trust violations, please email us at [email protected]

SOURCE Weiss’ Law

Comments are closed.